Literature DB >> 33732287

Mutational Spectrum of LDLR and PCSK9 Genes Identified in Iranian Patients With Premature Coronary Artery Disease and Familial Hypercholesterolemia.

Arman Moradi1, Majid Maleki2, Zahra Ghaemmaghami2, Zahra Khajali2, Feridoun Noohi2, Maryam Hosseini Moghadam2, Samira Kalyinia2, Seyed Javad Mowla1, Nabil G Seidah3, Mahshid Malakootian2.   

Abstract

Familial hypercholesterolemia (FH) is a common, yet underdiagnosed, genetic disorder characterized by lifelong elevated low-density lipoprotein cholesterol levels, which can increase the risk of early-onset coronary artery disease (CAD). In the present study, we screened the nucleotide variations of the LDLR and PCSK9 genes, as well as a part of the APOB gene, in Iranian patients with FH and premature CAD to find the genetic cause of the disorder. Fifteen unrelated individuals with a clinical diagnosis of FH and premature CAD were recruited. Direct DNA sequencing was applied to screen the whole coding exons and exon-intron boundaries of the LDLR and PCSK9 genes and the main parts of their introns, together with exon 26 of the APOB gene. The pathogenicity of the identified mutations was investigated via either segregation analyses in the family or in silico predictive software. Six different point mutations (p.Cys148Tyr, p.Cys216Tyr, p.Cys302Trp, p.Cys338Trp, p.Leu479Gln, and p.G593Afs∗72) in LDLR and a double mutation (p.Asp172His and p.Ala53Val) in both LDLR and PCSK9 genes were identified in seven families with clinically diagnosed FH (43%), whereas no pathogenic mutations were found in eight families with clinically diagnosed FH. This study is the first to identify 1 pathogenic mutation in the LDLR gene (c.1014C > G [p.Cys338Trp]) and to cosegregate it from the affected individual in the family. No mutations were found in the APOB gene, whereas several silent mutations/polymorphisms were identified in the LDLR and PCSK9 genes. Genetic testing and reports on nucleotide alterations in the Iranian population are still limited. Our findings not only further confirm the significant role of FH in the incidence of premature CAD but also enlarge the spectrum of LDLR and PCSK9 variations and exhibit the heterogeneity of FH in Iranians. In patients with no mutation in the examined genes, the disease could be begotten either by a polygenic cause or by gene defects occurring in other related genes and regions not targeted in this study.
Copyright © 2021 Moradi, Maleki, Ghaemmaghami, Khajali, Noohi, Moghadam, Kalyinia, Mowla, Seidah and Malakootian.

Entities:  

Keywords:  Familial Hypercholesterolemia; LDLR; PCSK9 (proprotein convertase subtilisin kexin type 9); loss-of-function; pre-mature CAD

Year:  2021        PMID: 33732287      PMCID: PMC7959244          DOI: 10.3389/fgene.2021.625959

Source DB:  PubMed          Journal:  Front Genet        ISSN: 1664-8021            Impact factor:   4.599


  55 in total

1.  A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom.

Authors:  K E Heath; S E Humphries; H Middleton-Price; M Boxer
Journal:  Eur J Hum Genet       Date:  2001-04       Impact factor: 4.246

2.  Identification of recurrent and novel mutations in the LDL receptor gene in German patients with familial hypercholesterolemia.

Authors:  M S Nauck; W Köster; K Dörfer; J Eckes; H Scharnagl; H Gierens; H Nissen; M A Nauck; H Wieland; W März
Journal:  Hum Mutat       Date:  2001-08       Impact factor: 4.878

3.  An Iranian-Armenian LDLR frameshift mutation causing familial hypercholesterolemia.

Authors:  H K Jensen; L G Jensen; P S Hansen; O Faergeman; N Gregersen
Journal:  Clin Genet       Date:  1996-02       Impact factor: 4.438

4.  Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects.

Authors:  Sabina O Beheshti; Christian M Madsen; Anette Varbo; Børge G Nordestgaard
Journal:  J Am Coll Cardiol       Date:  2020-05-26       Impact factor: 24.094

Review 5.  The UMD-LDLR database: additions to the software and 490 new entries to the database.

Authors:  Ludovic Villéger; Marianne Abifadel; Delphine Allard; Jean-Pierre Rabès; Rochelle Thiart; Maritha J Kotze; Christophe Béroud; Claudine Junien; Catherine Boileau; Mathilde Varret
Journal:  Hum Mutat       Date:  2002-08       Impact factor: 4.878

6.  An extracellular beta-propeller module predicted in lipoprotein and scavenger receptors, tyrosine kinases, epidermal growth factor precursor, and extracellular matrix components.

Authors:  T A Springer
Journal:  J Mol Biol       Date:  1998-11-06       Impact factor: 5.469

7.  Hyperlipoproteinaemia(a) is a common cause of autosomal dominant hypercholesterolaemia.

Authors:  E Meriño-Ibarra; J Puzo; E Jarauta; A Cenarro; D Recalde; A L García-Otín; E Ros; E Martorell; X Pintó; M Franco; D Zambón; A Brea; M Pocoví; F Civeira
Journal:  J Inherit Metab Dis       Date:  2007-10-20       Impact factor: 4.982

8.  Post-transcriptional Regulation of PCSK9 by miR-191, miR-222, and miR-224.

Authors:  Parisa Naeli; Fatemeh Mirzadeh Azad; Mahshid Malakootian; Nabil G Seidah; Seyed J Mowla
Journal:  Front Genet       Date:  2017-11-27       Impact factor: 4.599

9.  The Genetic Spectrum of Familial Hypercholesterolemia (FH) in the Iranian Population.

Authors:  R H Fairoozy; M Futema; R Vakili; M R Abbaszadegan; S Hosseini; M Aminzadeh; H Zaeri; M Mobini; S E Humphries; A Sahebkar
Journal:  Sci Rep       Date:  2017-12-06       Impact factor: 4.379

10.  Loss-of-function mutation of PCSK9 as a protective factor in the clinical expression of familial hypercholesterolemia: A case report.

Authors:  Ane Bayona; Francisco Arrieta; Carmen Rodríguez-Jiménez; Francisco Cerrato; Sonia Rodríguez-Nóvoa; Milagros Fernández-Lucas; Diego Gómez-Coronado; Pedro Mata
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817

View more
  1 in total

Review 1.  Potential of Phage Display Antibody Technology for Cardiovascular Disease Immunotherapy.

Authors:  Soo Ghee Yeoh; Jia Siang Sum; Jing Yi Lai; W Y Haniff W Isa; Theam Soon Lim
Journal:  J Cardiovasc Transl Res       Date:  2021-08-31       Impact factor: 3.216

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.